Dermira Company Profile (NASDAQ:DERM)

About Dermira

Dermira logoDermira, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies for dermatologic diseases. The Company's portfolio includes three late-stage product candidates that target unmet needs and market opportunities, such as Cimzia (certolizumab pegol), DRM04 and DRM01. Cimzia is an injectable biologic tumor necrosis factor-alpha inhibitor, or TNF inhibitor, that is approved and marketed for the treatment of numerous inflammatory diseases spanning multiple medical specialties, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn's disease. DRM04 is a topical, small-molecule anticholinergic product for the treatment of hyperhidrosis. DRM01 is a topical, small-molecule sebum inhibitor for the treatment of acne.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: DERM
  • CUSIP:
Key Metrics:
  • Previous Close: $33.82
  • 50 Day Moving Average: $32.75
  • 200 Day Moving Average: $28.97
  • 52-Week Range: $17.42 - $36.16
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -10.47
  • P/E Growth: 0.00
  • Market Cap: $1.20B
  • Outstanding Shares: 35,379,000
  • Beta: 0.86
Profitability:
  • Return on Equity: -48.98%
  • Return on Assets: -41.85%
Debt:
  • Current Ratio: 11.95%
  • Quick Ratio: 11.95%
Additional Links:
Companies Related to Dermira:

Analyst Ratings

Consensus Ratings for Dermira (NASDAQ:DERM) (?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $44.75 (32.32% upside)

Analysts' Ratings History for Dermira (NASDAQ:DERM)
Show:
DateFirmActionRatingPrice TargetDetails
9/21/2016Needham & Company LLCReiterated RatingBuy$46.00View Rating Details
6/2/2016Leerink SwannReiterated RatingBuy$46.00 -> $47.00View Rating Details
6/2/2016WedbushBoost Price TargetOutperform$42.00 -> $46.00View Rating Details
3/16/2016Citigroup Inc.Lower Price TargetBuy$42.00 -> $40.00View Rating Details
8/19/2015Cowen and CompanyInitiated CoverageOutperform$40.00View Rating Details
8/7/2015GuggenheimBoost Price TargetBuy$22.00 -> $40.00View Rating Details
(Data available from 10/1/2014 forward)

Earnings

Earnings History for Dermira (NASDAQ:DERM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2016        
8/8/2016Q2($0.86)($0.89)ViewN/AView Earnings Details
5/10/2016Q1($0.94)($0.95)ViewListenView Earnings Details
3/3/2016Q4($0.95)($1.04)ViewListenView Earnings Details
11/10/2015Q3($0.77)($0.58)ViewN/AView Earnings Details
8/13/2015Q2($0.81)($0.69)ViewN/AView Earnings Details
5/12/2015Q1($0.65)($0.57)ViewN/AView Earnings Details
3/25/2015Q4($0.59)($0.29)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Dermira (NASDAQ:DERM)
Current Year EPS Consensus Estimate: $-3.52 EPS
Next Year EPS Consensus Estimate: $-3.23 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($1.00)($1.00)($1.00)
Q2 20161($0.96)($0.96)($0.96)
Q3 20161($0.64)($0.64)($0.64)
Q4 20161($0.94)($0.94)($0.94)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Dermira (NASDAQ:DERM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Dermira (NASDAQ:DERM)
Insider Ownership Percentage: 17.30%
Institutional Ownership Percentage: 82.46%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/19/2016Andrew GuggenhimeCFOSell15,000$35.01$525,150.00View SEC Filing  
9/15/2016Christopher M GriffithVPSell1,303$33.26$43,337.78View SEC Filing  
9/12/2016Andrew GuggenhimeCFOSell10,000$32.53$325,300.00View SEC Filing  
9/1/2016Thomas G WiggansCEOSell11,000$31.63$347,930.00View SEC Filing  
9/1/2016William R RingoDirectorSell500$32.00$16,000.00View SEC Filing  
8/15/2016Christopher M GriffithVPSell1,303$31.75$41,370.25View SEC Filing  
8/11/2016Andrew GuggenhimeCFOSell10,000$31.02$310,200.00View SEC Filing  
8/1/2016Eugene A BauerInsiderSell2,500$33.18$82,950.00View SEC Filing  
8/1/2016Thomas G WiggansCEOSell11,000$33.19$365,090.00View SEC Filing  
8/1/2016William R RingoDirectorSell500$33.65$16,825.00View SEC Filing  
7/15/2016Christopher M GriffithVPSell1,303$30.02$39,116.06View SEC Filing  
7/11/2016Andrew GuggenhimeCFOSell10,000$30.15$301,500.00View SEC Filing  
7/5/2016Thomas G WiggansCEOSell11,000$29.62$325,820.00View SEC Filing  
7/1/2016Eugene A BauerInsiderSell2,500$29.48$73,700.00View SEC Filing  
6/23/2016Luis C PenaInsiderSell10,000$30.01$300,100.00View SEC Filing  
6/15/2016Luis C PenaInsiderSell10,000$29.47$294,700.00View SEC Filing  
6/13/2016Christopher M GriffithVPSell4,405$30.16$132,854.80View SEC Filing  
6/1/2016Eugene A BauerInsiderSell2,500$31.65$79,125.00View SEC Filing  
6/1/2016Thomas G WiggansCEOSell11,000$31.57$347,270.00View SEC Filing  
5/2/2016Eugene A BauerInsiderSell2,500$25.09$62,725.00View SEC Filing  
5/2/2016Thomas G WiggansCEOSell9,000$25.11$225,990.00View SEC Filing  
4/1/2016Eugene A BauerInsiderSell2,500$20.84$52,100.00View SEC Filing  
4/1/2016Thomas G WiggansCEOSell7,000$20.69$144,830.00View SEC Filing  
3/1/2016Eugene A BauerInsiderSell2,500$22.55$56,375.00View SEC Filing  
3/1/2016Thomas G WiggansCEOSell7,000$22.57$157,990.00View SEC Filing  
2/1/2016Eugene A BauerInsiderSell2,500$27.26$68,150.00View SEC Filing  
2/1/2016Thomas G WiggansCEOSell9,000$27.25$245,250.00View SEC Filing  
1/4/2016Eugene A BauerInsiderSell2,500$33.17$82,925.00View SEC Filing  
1/4/2016Thomas G WiggansCEOSell11,000$33.17$364,870.00View SEC Filing  
12/1/2015Eugene A BauerInsiderSell2,500$29.65$74,125.00View SEC Filing  
11/2/2015Eugene A BauerInsiderSell2,500$27.82$69,550.00View SEC Filing  
10/1/2015Eugene A BauerInsiderSell2,500$22.87$57,175.00View SEC Filing  
9/14/2015Eugene A BauerInsiderSell22,500$28.05$631,125.00View SEC Filing  
11/25/2014Matthew K FustDirectorBuy6,000$16.77$100,620.00View SEC Filing  
10/8/2014Bay City Capital LlcDirectorBuy69,112$16.00$1,105,792.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Dermira (NASDAQ:DERM)
DateHeadline
News IconStock within investor Spotlight: GTT Communications, Inc. (NYSE:GTT) , Dermira, Inc. (NASDAQ:DERM) - Wall Street Times (press release) (NASDAQ:DERM)
www.wallstreetnews24.com - September 28 at 9:30 AM
News IconHow Analysts Rated Dermira Inc (NASDAQ:DERM) Last Week? - Post News (NASDAQ:DERM)
www.kentuckypostnews.com - September 28 at 9:30 AM
News IconDermira, Inc. (NASDAQ:DERM) – Broker Update - NewsDen (NASDAQ:DERM)
newsden.net - September 28 at 9:30 AM
globenewswire.com logoDermira to Present Data from DRM04 Phase 3 Clinical Trials at Late-Breaking News Session at European Academy of ... - GlobeNewswire (press release) (NASDAQ:DERM)
globenewswire.com - September 28 at 9:30 AM
finance.yahoo.com logoDermira to Present Data from DRM04 Phase 3 Clinical Trials at Late-Breaking News Session at European Academy of Dermatology and Venereology Congress (NASDAQ:DERM)
finance.yahoo.com - September 28 at 9:30 AM
News IconExpert Analysts Consensus Opinions for: Caleres, Inc. (NYSE:CAL) , Dermira, Inc. (NASDAQ:DERM) - Wall Street Times (press release) (NASDAQ:DERM)
www.wallstreetnews24.com - September 23 at 4:23 PM
4-traders.com logoDERMIRA, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K) (NASDAQ:DERM)
www.4-traders.com - September 23 at 9:39 AM
biz.yahoo.com logoDERMIRA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits (NASDAQ:DERM)
biz.yahoo.com - September 23 at 9:39 AM
investornewswire.com logoShares Of Dermira, Inc. (NASDAQ:DERM) Expected To Hit $47 - Investor Newswire (NASDAQ:DERM)
www.investornewswire.com - September 22 at 4:42 PM
reuters.com logoBRIAN DEALTALK-Allergan pays top dollar for 'stepping stones' from neurology to dermatology (NASDAQ:DERM)
uk.reuters.com - September 22 at 10:10 AM
seekingalpha.com logoNovan's IPO - Buying A Dollar For Twenty Cents (NASDAQ:DERM)
seekingalpha.com - September 22 at 10:10 AM
News IconStocks within Analyst Limelight: Dermira, Inc. (NASDAQ:DERM) , Acxiom Corporation (NASDAQ:ACXM) - Wall Street Times (press release) (NASDAQ:DERM)
www.wallstreetnews24.com - September 21 at 8:53 AM
globenewswire.com logoDermira Licenses DRM04 to Maruho for Hyperhidrosis in Japan ... - GlobeNewswire (press release) (NASDAQ:DERM)
www.globenewswire.com - September 21 at 8:53 AM
News IconIs Dermira Inc's Fuel Running Low? The Stock Reaches 52-Week ... - Post News (NASDAQ:DERM)
www.kentuckypostnews.com - September 21 at 8:53 AM
publicnow.com logoDermira Licenses DRM04 to Maruho for Hyperhidrosis in Japan (NASDAQ:DERM)
www.publicnow.com - September 21 at 8:53 AM
News IconWhat after Christopher Griffith's Insider Sale of Dermira Inc (NASDAQ:DERM) Stock? - Post News (NASDAQ:DERM)
www.kentuckypostnews.com - September 20 at 8:17 AM
News IconDermira Inc (DERM) PT Raised to $46.00 - Daily Quint || dailyquint ... - DailyQuint (NASDAQ:DERM)
dailyquint.com - September 18 at 4:28 PM
News IconStock Intraday Alert: Dermira, Inc. (NASDAQ:DERM) , Exar ... - Wall Street Times (press release) (NASDAQ:DERM)
www.wallstreetnews24.com - September 16 at 8:17 AM
capitalcube.com logoDermira, Inc. breached its 50 day moving average in a Bullish Manner : DERM-US : September 15, 2016 (NASDAQ:DERM)
www.capitalcube.com - September 15 at 8:24 AM
streetinsider.com logoDermira (DERM) Enters Exclusive Option and License Agreement with Takeda - StreetInsider.com (NASDAQ:DERM)
www.streetinsider.com - September 14 at 8:46 AM
investornewswire.com logoDermira, Inc. (NASDAQ:DERM) Reported An Earnings Surprise Of 7.29 Percent - Investor Newswire (NASDAQ:DERM)
www.investornewswire.com - September 14 at 8:46 AM
bloomberg.com logoMost Japanese Shares Rise as Investors Look to Fed, BOJ Meetings (NASDAQ:DERM)
washpost.bloomberg.com - September 13 at 9:28 AM
bloomberg.com logoJapanese Shares Fall as Banks, Insurers Drop on BOJ Outlook (NASDAQ:DERM)
www.bloomberg.com - September 13 at 9:28 AM
News IconDermira acquires option to license exclusive rights for up to 3 small-molecule programmes for skin diseases from Takeda (NASDAQ:DERM)
www.pharmabiz.com - September 13 at 9:28 AM
globenewswire.com logoDermira Acquires Option to License Exclusive Rights for up to Three ... - GlobeNewswire (press release) (NASDAQ:DERM)
www.globenewswire.com - September 12 at 4:24 PM
News IconStocks on Trader's Radar - Dermira, Inc. (NASDAQ:DERM) , Eaton Vance Floating Rate Income Trust (NYSE:EFT) - Wall Street Times (press release) (NASDAQ:DERM)
www.wallstreetnews24.com - September 12 at 4:24 PM
News IconDermira Inc. Pipeline Review 2016- Market Outlook, Share, Growth, Supply Revenue and Forecast 2021 - Medgadget (blog) (NASDAQ:DERM)
www.medgadget.com - September 12 at 4:24 PM
reuters.com logoBRIEF-Dermira acquires option to license exclusive rights for up to three early-stage programs from Takeda (NASDAQ:DERM)
www.reuters.com - September 12 at 9:31 AM
finance.yahoo.com logo7:31 am Dermira acquires Option to License Exclusive Rights for up to Three Early-Stage Programs from Takeda (TKPYY (NASDAQ:DERM)
finance.yahoo.com - September 12 at 9:31 AM
publicnow.com logoDermira Acquires Option to License Exclusive Rights for up to Three Early-Stage Programs from Takeda (NASDAQ:DERM)
www.publicnow.com - September 12 at 9:31 AM
News IconDermira Inc. Pipeline Review 2016- Market Outlook, Share, Growth, Supply Revenue and Forecast 2021 (NASDAQ:DERM)
www.medgadget.com - September 11 at 4:24 PM
News IconRegents Of The University Of California Exits Position in Dermira Inc ... - National Daily Press (NASDAQ:DERM)
www.nationaldailypress.com - September 11 at 9:06 AM
News IconAnalyst Consensus Estimates & Projections are in For Shares of Dermira, Inc. (NASDAQ:DERM) - Frisco Fastball (NASDAQ:DERM)
friscofastball.com - September 10 at 9:12 AM
capitalcube.com logoDermira, Inc. – Value Analysis (NASDAQ:DERM) : September 6, 2016 (NASDAQ:DERM)
www.capitalcube.com - September 6 at 4:29 PM
fidaily.com logoDermira, Inc. (NASDAQ:DERM) Trading Up - Insiders Selling, Short Interest Growing - Finance Daily (NASDAQ:DERM)
www.fidaily.com - September 2 at 4:33 PM
capitalcube.com logoDermira, Inc. breached its 50 day moving average in a Bullish Manner : DERM-US : September 2, 2016 (NASDAQ:DERM)
www.capitalcube.com - September 2 at 9:27 AM
News IconShares Slipping Lower Over the Past Month: Dermira, Inc. (NASDAQ:DERM) - Post News (NASDAQ:DERM)
www.kentuckypostnews.com - September 1 at 9:27 AM
investornewswire.com logoWill Dermira, Inc. (NASDAQ:DERM) Surprise This Quarter? - Investor Newswire (NASDAQ:DERM)
www.investornewswire.com - August 28 at 4:17 PM
investornewswire.com logoDermira, Inc. (NASDAQ:DERM) Gets 0 Recommendations To Sell - Investor Newswire (NASDAQ:DERM)
www.investornewswire.com - August 25 at 4:38 PM
investornewswire.com logoWill Dermira, Inc. (NASDAQ:DERM) Hit $47 Price Target? - Investor Newswire (NASDAQ:DERM)
www.investornewswire.com - August 18 at 8:48 AM
finance.yahoo.com logoDERMIRA, INC. Financials (NASDAQ:DERM)
finance.yahoo.com - August 17 at 4:46 PM
nasdaq.com logoCommit To Buy Dermira At $30, Earn 22.9% Annualized Using Options (NASDAQ:DERM)
www.nasdaq.com - August 16 at 4:41 PM
fidaily.com logoDermira, Inc. (DERM) Ownership Up in Latest Report from Timessquare Capital Management, LLC - Finance Daily (NASDAQ:DERM)
www.fidaily.com - August 11 at 4:43 PM
reuters.com logoBRIEF-Dermira reports Q2 loss per share $0.89 (NASDAQ:DERM)
www.reuters.com - August 9 at 8:58 AM
twst.com logoDermira Inc.: Dermira Reports Second Quarter 2016 Financial Results and Provides Corporate Update (NASDAQ:DERM)
www.twst.com - August 9 at 8:58 AM
sg.finance.yahoo.com logoDermira reports 2Q loss (NASDAQ:DERM)
sg.finance.yahoo.com - August 9 at 8:58 AM
twst.com logoDermira Inc.: Dermira Reports Second Quarter 2016 Financial Results and Provides Corporate Update - The Wall Street Transcript (NASDAQ:DERM)
www.twst.com - August 8 at 9:57 PM
4-traders.com logoDERMIRA, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K) (NASDAQ:DERM)
www.4-traders.com - August 8 at 4:42 PM
biz.yahoo.com logoDERMIRA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits (NASDAQ:DERM)
biz.yahoo.com - August 8 at 4:42 PM
publicnow.com logoDermira Reports Second Quarter 2016 Financial Results and Provides Corporate Update (NASDAQ:DERM)
www.publicnow.com - August 8 at 4:42 PM

Social

Dermira (NASDAQ:DERM) Chart for Saturday, October, 1, 2016


Last Updated on 10/1/2016 by MarketBeat.com Staff